🔗 Share this article

The recently developed medications for gonorrhoea in many years are being hailed as a "huge turning point" in the fight against drug-resistant strains of the bacteria, according to scientists.

A Global Health Concern

The sexually transmitted infection are increasing globally, with data suggesting over 82 million instances each year. Particularly high rates are reported in Africa and countries within the World Health Organization's designated area, which spans from Mongolia and China to New Zealand. Across England, cases have hit a all-time high, while infection numbers across Europe in 2023 were triple the level compared to the rates from 2014.

“The authorization of fresh medications for gonorrhoea is an important and timely step in the face of growing infection rates, increasing antimicrobial resistance and the highly restricted available drugs currently available.”

Health officials are deeply concerned about the rise in antibiotic-resistant strains. The World Health Organization has classified it as a "priority pathogen". Recent surveillance found that resistance to standard treatments like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Therapies Receive Clearance

One new antibiotic, alternatively called Nuzolvence, was cleared by the American regulatory agency in recent days for use against gonorrhoea. This STI can lead to significant complications, including infertility. Researchers believe that focused deployment of this new drug will help slow the spread of drug resistance.

Gepotidacin, developed by the drugmaker GSK, also received approval in the same week. This treatment, which is also used to treat UTIs, was demonstrated in studies to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Approach to Creation

Zoliflodacin was the result of a new, not-for-profit approach for drug creation. The non-profit organisation GARDP worked alongside the drug firm Innoviva to develop it.

“This milestone marks a major breakthrough in the management of highly resistant gonorrhoea, which up to this point has been staying ahead of antibiotic development.”

Testing Data and Global Access

Based on findings published in a major medical journal, zoliflodacin successfully treated over nine in ten of genital gonorrhoea infections. This establishes an equal footing with the existing first-line therapy, which uses two antibiotics. The trial included hundreds of patients from various regions including the United States, Thailand, South Africa, and European nations.

Under the terms of its unique model, GARDP has the ability to license and sell the drug in numerous regions with limited resources.

Medical professionals on the front lines have shared positive views. The availability of a single-dose, oral treatment of this kind is hailed as a "revolutionary step" for public health efforts. This is viewed as crucial to reduce the burden of the infection for individuals and to halt the transmission of untreatable gonorrhoea around the world.